Vaxelis + PedvaxHIB
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Haemophilus Influenzae Type B Infection
Conditions
Haemophilus Influenzae Type B Infection
Trial Timeline
Jan 27, 2022 → Oct 26, 2023
NCT ID
NCT04978818About Vaxelis + PedvaxHIB
Vaxelis + PedvaxHIB is a approved stage product being developed by Merck for Haemophilus Influenzae Type B Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT04978818. Target conditions include Haemophilus Influenzae Type B Infection.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04978818 | Approved | Completed |
Competing Products
10 competing products in Haemophilus Influenzae Type B Infection
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Comparator: Modified Process Vaccine + Comparator: COMVAX™ | Merck | Phase 3 | 77 |
| Haemophilus influenzae type b (Hib) vaccine | Novartis | Phase 3 | 77 |
| Haemophilus influenzae type b (Hib) vaccine | Novartis | Phase 3 | 77 |
| Haemophilus influenza type b conjugate vaccine | Novartis | Approved | 85 |
| Hib-CRM197 + Hib-TT | Novartis | Phase 3 | 77 |
| Vaxem Hib (Haemophilus influenzae type b (Hib) vaccine) + Hiberix (Haemophilus influenzae type b (Hib) vaccine) | Novartis | Phase 3 | 77 |
| Haemophilus influenzae type b | Novartis | Phase 1 | 33 |
| Monovalent glyco-conjugated vaccine against Haemophilus influenzae type b (Hib) + Tetanus toxoid polysaccharide-conjugated vaccine against Haemophilus influenzae type b (Hib) | Novartis | Phase 3 | 77 |
| Haemophilus influenzae type b vaccine + Commercial Haemophilus influenzae type b vaccine | Novartis | Phase 3 | 77 |
| DTaP-IPV/Hib | Sanofi | Pre-clinical | 22 |